Abstract
Our results confirm that FMT is a safe, efficacious, and feasible intervention for patients with refractory or recurrent CDI in Hong Kong. Given the increasing disease burden and the lack of effective alternatives in Hong Kong for difficult-to-treat cases of CDI, we recommend that a territory-wide FMT service be established to address increasing demand for this treatment.
Introduction
Clostridioides difficile infection (CDI) represents a significant global healthcare challenge, typically arising when antibiotic use disrupts the gut microbiome's natural balance. In Hong Kong, the situation is increasingly urgent, with CDI incidence rising by 26% annually between 2006 and 2014. For patients suffering from recurrent or refractory cases—where standard therapies like vancomycin fail—there is a critical treatment gap. This study evaluates the efficacy and safety of Faecal Microbiota Transplantation (FMT) within the Hong Kong healthcare context.
Methods
Researchers conducted a single-centre, retrospective study at an academic hospital, reviewing 24 consecutive cases of difficult-to-treat CDI between 2013 and 2018. The protocol evolved from using screened relatives as donors to utilizing a "Healthy Donor Stool Biobank" established by the Chinese University of Hong Kong. This biobank provided pre-screened frozen stools, which underwent rigorous testing for a wide array of pathogens, including multidrug-resistant organisms. FMT was administered via three primary routes: feeding tubes (45.8%), esophagogastroduodenoscopy (33.3%), or colonoscopy (25.0%), with most patients receiving a standardized dose of 50g of FMT product.
Results and Patient Profile
The study cohort consisted of 24 patients with a median age of 70 years. This was a high-risk group, with over 80% having been recently hospitalized or residing in long-term care facilities. Comorbidities were prevalent, including hypertension, inflammatory bowel disease, and stroke.
Primary efficacy was high, with 21 out of 24 patients (87.5%) achieving resolution of diarrhea without relapse within 8 weeks of a single FMT. The three patients who did not respond to the initial treatment underwent a second FMT, and all three subsequently recovered, resulting in a 100% ultimate success rate for the cohort. Safety outcomes were excellent; there were no deaths within 30 days and no serious adverse events attributable to the procedure. Minor complications were limited to transient abdominal discomfort (12.5%) and bloating (4.2%).
Discussion
FMT functions as an ecological restoration, replenishing microbial diversity to eliminate the niches that C. difficile exploits. Notably, the 87.5% success rate observed in Hong Kong is remarkably consistent with results reported in Western literature, suggesting that FMT's efficacy is robust across different dietary and environmental backgrounds. The transition to a centralized stool biobank represents a major advancement in feasibility, allowing for "off-the-shelf" treatment and rapid intervention.
Conclusion and Future Directions
While limited by a small sample size and retrospective design, this study confirms that FMT is a safe and highly effective intervention for refractory or recurrent CDI, even in elderly and medically complex populations. To address the rising disease burden, the authors advocate for the establishment of a territory-wide FMT service in Hong Kong. Such a service would involve multidisciplinary teams and a centralized registry to optimize treatment timing and monitor long-term safety.
Summary updated